Bavarian Nordic says Phase 2 trial supports EU approval of IMVANEX mpox vaccine in children 2-11

• Bavarian Nordic secured European Commission clearance to expand IMVANEX use to children aged 2 to under 12.
• The decision relied on results already generated in a Phase 2 trial comparing children with adults.
• The study showed children produced an immune response comparable to adults with a similar safety profile.
• The label expansion broadens EU access to the company’s non-replicating MVA-BN vaccine for mpox and smallpox preparedness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070200OMX_____CNEWS_DA_GNW1001256491_da) on August 07, 2026, and is solely responsible for the information contained therein.